TAA Polyepitope DNA-Based Vaccines: A Potential Tool for Cancer Therapy
Authors:
Open Access
- 17 June 2010
- journal article
- review article
- Published by Wiley in Journal of Biomedicine and Biotechnology
- Vol. 2010, 1-12
Abstract
DNA-based cancer vaccines represent an attractive strategy for inducing immunity to tumor associated antigens (TAAs) in cancer patients. The demonstration that the delivery of a recombinant plasmid encoding epitopes can lead to epitope production, processing, and presentation to CD8+ T-lymphocytes, and the advantage of using a single DNA construct encoding multiple epitopes of one or more TAAs to elicit a broad spectrum of cytotoxic T-lymphocytes has encouraged the development of a variety of strategies aimed at increasing immunogenicity of TAA polyepitope DNA-based vaccines. The polyepitope DNA-based cancer vaccine approach can (a) circumvent the variability of peptide presentation by tumor cells, (b) allow the introduction in the plasmid construct of multiple immunogenic epitopes including heteroclitic epitope versions, and (c) permit to enroll patients with different major histocompatibility complex (MHC) haplotypes. This review will discuss the rationale for using the TAA polyepitope DNA-based vaccination strategy and recent results corroborating the usefulness of DNA encoding polyepitope vaccines as a potential tool for cancer therapy.Keywords
This publication has 97 references indexed in Scilit:
- Immune surveillance of human cancer: if the cytotoxic T‐lymphocytes play the music, does the tumoral system call the tune?Tissue Antigens, 2009
- Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized TrialClinical Cancer Research, 2009
- Multipeptide vaccination in cancer patientsExpert Opinion on Biological Therapy, 2009
- Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancerThe Prostate, 2009
- Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/− Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-α2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696Clinical Cancer Research, 2009
- Cancer related inflammation: The macrophage connectionCancer Letters, 2008
- DNA vaccines: precision tools for activating effective immunity against cancerNature Reviews Cancer, 2008
- A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor ChallengeCancer Research, 2007
- DNA Vaccines Encoding Ii-PADRE Generates Potent PADRE-specific CD4+ T-Cell Immune Responses and Enhances Vaccine PotencyMolecular Therapy, 2007
- Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancerSurgery, 2006